Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.


TechCrunch
OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation | TechCrunch
Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.


















